Covid 19 vaccine, Adverse drug reactions, Vaccination, ChAdOx1 nCoV-19 vaccine


Objective: The present study aimed to ensure the safety and related potential adverse effects following ChAdOx1 nCoV-19 vaccination (AZD1222) in a scenario when numerous vaccines have been approved on an emergency basis by the WHO and other regulatory agencies to prevent the widespread of COVID-19 infection and to decrease the associated mortality and morbidity.

Methods: This study was an open, non-comparative, non-interventional, observational study conducted on healthcare workers of BPS Govt. medical college for women and elderly people who received the first dose of COVID-19 vaccinationChAdOx1 nCoV-19 vaccine (AZD1222) by conducting their interviews and recording the data

Results: Between January and March 2021, a total of 1907 participants were enrolled in this study. Out of 1907 recipients, 70 recipients reports adverse drug events following vaccination. Myalgia (0.629%), headache (1.31%), fever (≥ 37.5 °C, 0.839%) and fever with chills (≥ 37.5 °C, 1.048) were the most common adverse events after the first dose of vaccination of ChAdOx1 nCoV-19 vaccine (AZD1222. Throat irritation (0.209 %) and Generalised itching (0.262) were the least common adverse events.

Conclusion: ChAdOx1 nCoV-19 (Astrazeneca) has an acceptable safety profile as observed in this study. To our knowledge, very few studies are done that review the safety of COVID-19 vaccines. Further safety data from a larger sample size and of longer duration are warranted to establish safety


Download data is not yet available.


World Health Organization. COVID-19 vaccines: safety surveillance manual; 2020. [Last accessed on 28 Jan 2021]

Narwat A, Rani S, Bhutani G, Saini R, Singh K. New coronavirus: is just a tip of iceberg? Int J Basic Clin Pharmacol. 2020;9(7):1147-52. doi: 10.18203/2319-2003.ijbcp20202957.

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: [Last accessed on 28 Jan 2021]

RAPS CJ. COVID-19 vaccine tracker; 2021. [Last accessed on 23 Jan 2021].

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij Rammerstorfer S. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet. 2020;396(10249):467-78. doi: 10.1016/S0140-6736(20)31604-4, PMID 32702298.

Fact sheet for vaccine recipient approved for restricted use in emergency situation of chadox1 ncov-19 coronavirus vaccine (recombinant). Available from: https://www,com.serum institute serum institute. [Last accessed on 19 Aug 2021]

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1, PMID 33306989.

Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427-39. doi: 10.1007/s12291-021-00968-z. PMID 33814753.

Yamamoto K. Adverse effects of COVID-19 vaccines and measures to prevent them. Virol J. 2022;19(1):100. doi: 10.1186/s12985-022-01831-0, PMID 35659687.

Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021; 4(12):e2140364. doi: 10.1001/jamanetworkopen.2021.40364. PMID 34935921.

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021 Jul;21(7):939-49. doi: 10.1016/S1473-3099(21)00224-3, PMID 33930320.

Administration FaD: emergency use authorization for vaccines to prevent COVID-19: guidance for industry; 2020. [Last accessed on 31 Jan 2021].



How to Cite

NARWAT, A., M. DUA, and A. GOYAL. “SAFETY MONITORING OF COVID-19 VACCINE: IN A TERTIARY CARE HOSPITAL IN HARYANA”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 15, no. 3, Mar. 2023, pp. 35-37, doi:10.22159/ijpps.2023v15i3.47287.



Original Article(s)